icon- folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
 
 
Doravirine, Islatravir at AIDS2020 IAC
 
 
  Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naÏve participants from phase 3 clinical trials - (07/08/20)
 
ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
 
ISLATRAVIR (ISL, MK-8591) SAFETY ANALYSIS THROUGH WEEK 48 FROM A PHASE 2 TRIAL IN TREATMENT NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
 
WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)
 
Weight gain before and after switch from TDF to TAF - (07/07/20)
 
Early Weight Gain Up to 4.5 Kg/Year With Switch From TDF to TAF: Data Suggest Independent Effect of TAF on Weight - Mark Mascolini (07/06/20)
 
Only Small Weight Gains After Trial Switch to Doravirine/3TC/TDF - Mark Mascolini (07/06/20)
 
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (07/06/20) press release